Coronavirus vaccination in the UK could be just three months away, according to government figures.
Every adult in the country could be vaccinated against Covid-19 around Easter, once Easter is scheduled to train an army of auto workers to administer the shock.
It comes just days after it was claimed that rising coronavirus infection rates in the UK could actually speed up vaccination trials and move the world one step closer to eradicating the disease.
However, scientists are skeptical, saying it could take much longer to get a full vaccination, The Times reported.
Earlier this week, a report from the Royal Society warned that distributing and manufacturing the vaccine on such a mass scale would pose significant challenges.
Nilay Shah, Head of Chemical Engineering at Imperial College London and co-author of the report, said, “Even if the vaccine is available, it doesn't mean everyone will be vaccinated within a month.
Every adult in the country could be vaccinated against Covid-19 around Easter, as soon as Easter is scheduled to train an army of workers to manage the sting (file picture).
Nursing home residents and staff will be the first to receive a Covid-19 vaccine in front of NHS staff and anyone over 80
Nursing home residents and staff will be the first to receive a Covid-19 vaccine if approved, according to new government recommendations.
All over 80s and NHS staff will be in second place, updated guidelines from the Joint Committee on Vaccinating and Vaccinating States.
The body, which consists of 20 top scientists, advises the ministers on all vaccines. It admitted that its guidelines for a UK Covid-19 vaccination system are likely to change in the future.
Matt Hancock had previously pledged that Brits would be at the top of the queue with underlying terms for each push. But millions who live with heart disease or other diseases that increase their risk of dying from Covid-19 will not be vaccinated under the new guidelines until everyone over 65 is vaccinated.
WHO GETS A COVID-19 JAB FIRST?
According to the ranking proposed by the Joint Committee on Vaccination and Immunization, the vaccines will be introduced in the following order:
- older adults living in a nursing home and nursing home workers
- all these 80s and older as well as health and social workers
- all these 75 years and older
- all these 70 years and older
- all these 65 years and older
- High risk adults under 65 years of age with underlying health problems
- Intermediate risk adults under 65 years of age with underlying health problems
- all these 60 years and older
- all these 55 years and older
- all these 50 years and older
- Rest of the population (priority to be determined)
“We're talking about six months, nine months. . . a year. There is no question that life will suddenly go back to normal in March. & # 39;
Oxford University has been testing a vaccine on humans since April and there is hope that it could be approved by regulators by Christmas.
Government sources involved in the highly anticipated vaccine said it would take less than six months to complete a full program with no children.
Plans to speed up the process include establishing drive-through vaccination centers and rules that will allow more staff to give the shocks.
The armed forces could even be called in for additional help.
"We'll see you six months closer and it will likely be a lot shorter," a government source said.
Giving two doses of a vaccine to 53 million adults within a six month period would require 600,000 thrusts per day.
Those who need the injections most urgently are at the top of the list, which means that residents and nursing home staff will receive them as soon as they are ready.
Next up are people over 80 and NHS workers, followed by those over 65, younger adults at higher risk, and those over 50.
Some nursing home managers were asked last month for a list of eligible frontline workers.
Around 100 million doses of the Oxford vaccination, which has yet to prove successful, have already been ordered by the government.
Hopefully the scientists will know by the end of this year if it prevents at least 50 percent of infections, the threshold for success.
The UK is currently tied to the European Medicines Agency until January, which means it will not be able to administer the drug even if it has been approved by UK regulators.
However, ministers have announced plans to change the law so that vaccinations can start earlier.
The Ministry of Health said: "We are confident that we have sufficient supplies or transportation, PPE and logistics skills to deploy a Covid-19 vaccine across the country as soon as possible."
The Royal Society report highlighted several challenges, including the need to inject humans with RNA, a type of genetic material, in some of the most promising studies, even though an RNA vaccine has never been produced on a large scale.
Questions also remain about supply chains, with some vaccines having to be stored at -80 ° C during transport.
In addition, up to 80 percent of the population may need to be vaccinated to achieve herd immunity, even if a vaccine is found to be 90 percent effective at reducing transmission.
Prof. Shah added that around 20,000 people would need to be recruited by the NHS to dispense the drug and that field hospitals may need to be built for the mass vaccination program.
People enter Oxford Circus underground station in London after the 10 p.m. curfew that pubs and restaurants are subject to to combat the surge in coronavirus cases in England
It comes after it became known that New York-based Codagenix plans to begin experiments with its vaccine in London by the end of the year.
The sting will be of a type known as a live attenuated vaccine, which means that people are given a genetically modified version of the coronavirus that is weaker than the original but still contagious.
Live attenuated vaccines – like the MMR burst – stimulate the immune system in the same way as real Covid-19, but rely on viruses that cannot cause serious illness.
Codagenix says the vaccine was successful after a single dose in animal studies and is said to induce immunity to different parts of the coronavirus, rather than just the "spike protein" on the outside that many others have focused on.
This could mean that it will still work if the virus mutates. Using a live virus can allow medical professionals to create a type of immunity that naturally resembles that of the body.
The report comes after scientists suggested that the UK's soaring coronavirus infection rate could actually speed up vaccination trials and move the world one step closer to eradicating the disease.
The UK is really in the middle of a second wave now, with 6,000 new cases per day and hospital admissions doubling every week.
The British have been told they will have to live with tough new lockdown restrictions for another six months, with ministers having to take a bump until then.
Oxford University's lead vaccine candidate was due to launch this fall, but studies stalled when infection rates subsided over the summer.
Studies had to be relocated abroad to Brazil, the United States, and South Africa, where the coronavirus was still widespread, to test whether the sting could prevent infection.
To prove beyond any doubt that a vaccine works, scientists need to vaccinate tens of thousands of people, then send them back into the community and wait for some to get infected.
This was a sticking point for the Oxford team as there was barely any Covid-19 transmission in the UK for months. However, experts have told MailOnline that the only "silver lining" for rising Covid-19 rates in the UK is to speed up this process.
The UK is hosting the world's first "Challenge Trials" to accelerate COVID-19 vaccine development
British scientists will be the first in the world to conduct a controversial study in which volunteers race against time to find a vaccine are deliberately infected with coronavirus.
The "challenge attempt", which could quickly speed up approval of test shocks, is due to begin in January at a clinic in east London.
According to the Financial Times, participants will be infected with a dose of SARS-CoV-2, the virus that causes Covid-19, one month after being vaccinated.
The study, which was reportedly government funded, could help drug makers test their Covid-19 vaccines without waiting for volunteers to naturally catch the virus in the community.
It is expected that between 100 and 200 participants will be recruited for the study, which will be conducted by a U.S. advocacy group that has advocated human challenge trials throughout the pandemic.
It's unclear which vaccine candidate will be tested, but drug giants AstraZeneca and Sanofi have both insisted they not participate. MailOnline reached out to Imperial College London – Britain's other front runner – for comment on its involvement.
Often conducted by scientists trying to develop a vaccine, challenge studies have been used for malaria, typhoid, and flu. However, unlike these diseases, there is no proven treatment for people with mild coronavirus, so it doesn't stop participants from getting seriously ill.
The vaccine to be tested under the project has not been named and organizers are said to have designated a quarantine clinic operated by hVivo in Whitechapel, London, to conduct the trials.
Drug researcher hVivo is affiliated with Queen Mary University in London, while Imperial College London is considered the academic director of the project.
Around 2,000 potential volunteers have signed up to take part in challenge studies in the UK.
They did this through 1Day Sooner, a US-based advocacy group made up of 100 leading experts, including Nobel Prize winners.
(tagsToTranslate) Dailymail (t) Nachrichten (t) Coronavirus